Department of Endocrinology and Division of Laboratory Research, University of Duisburg-Essen, Essen, Germany.
Horm Metab Res. 2010 Jan;42(1):61-4. doi: 10.1055/s-0029-1238294. Epub 2009 Sep 4.
Nine patients (mean age 53) with metastasizing, progressive, medullary (MTC), thyroid carcinoma and progressive, nonradioiodine accumulating thyroid carcinoma of the follicular epithelium (follicular carcinoma, FTC and papillary carcinoma, PTC) were treated with a combination of paclitaxel and gemcitabine between 2004 and 2006. Tumors were histologically classified as follicular in 5 patients (56%), as papillary in 2 patients (22%), and medullary in 2 patients (22%). Paclitaxel (90-100 mg/m (2)) and gemcitabine (1,000 mg/m (2)) were applied for two, three, or 6 cycles every three weeks, depending on response and side effects. The effect of therapy was evaluated by radiographic imaging (CT images) and [(18)F]FDG-PET. All patients with papillary, follicular, or medullary thyroid carcinoma had continuous progression during restaging 14.8+/-8.8 weeks after initiation of chemotherapy, including one patient with stable disease after 3 cycles, but continuous progression after 6 cycles of chemotherapy. Paclitaxel and gemcitabine are not a valid chemotherapy option, in particular in patients with progressive, nonradioiodine-accumulating follicular thyroid carcinoma, who were already treated by other chemotherapeutic agents.
2004 年至 2006 年间，9 名患有转移性、进行性、髓样（MTC）甲状腺癌和进行性、非放射性碘积聚的滤泡上皮甲状腺癌（滤泡癌、FTC 和乳头状癌、PTC）的患者接受了紫杉醇和吉西他滨联合治疗。肿瘤的组织学分类为 5 例（56%）滤泡状、2 例（22%）乳头状和 2 例（22%）髓样。紫杉醇（90-100mg/m 2 ）和吉西他滨（1000mg/m 2 ）每三周应用 2、3 或 6 个周期，具体取决于反应和副作用。治疗效果通过影像学（CT 图像）和 [(18)F]FDG-PET 评估。所有患有乳头状、滤泡状或髓样甲状腺癌的患者在化疗开始后 14.8+/-8.8 周进行重新分期时均持续进展，包括 1 例在 3 个周期后病情稳定但在 6 个周期化疗后持续进展的患者。紫杉醇和吉西他滨不是有效的化疗选择，特别是对于已经接受其他化疗药物治疗的进行性、非放射性碘积聚的滤泡状甲状腺癌患者。
